Bausch Health Companies (BHC) Downgraded by ValuEngine

ValuEngine downgraded shares of Bausch Health Companies (NYSE:BHC) from a hold rating to a sell rating in a report published on Saturday, ValuEngine reports.

Other equities analysts have also issued research reports about the stock. Morgan Stanley set a $32.00 target price on shares of Bausch Health Companies and gave the company a buy rating in a report on Monday, December 17th. HC Wainwright upgraded shares of Bausch Health Companies from an average rating to a buy rating in a report on Friday, December 14th. Mizuho restated a buy rating and issued a $39.00 target price on shares of Bausch Health Companies in a report on Sunday, January 6th. UBS Group upgraded shares of Bausch Health Companies to a buy rating in a report on Wednesday, January 2nd. Finally, Zacks Investment Research upgraded shares of Bausch Health Companies from a hold rating to a buy rating and set a $28.00 target price on the stock in a report on Thursday, February 14th. Five equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the stock. Bausch Health Companies currently has an average rating of Hold and an average price target of $27.36.

Shares of NYSE:BHC opened at $24.34 on Friday. The firm has a market cap of $8.56 billion, a PE ratio of 6.05, a price-to-earnings-growth ratio of 0.62 and a beta of 0.59. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 8.55. Bausch Health Companies has a 52 week low of $16.76 and a 52 week high of $28.45.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, February 20th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.21. The company had revenue of $2.12 billion for the quarter, compared to analyst estimates of $2.08 billion. Bausch Health Companies had a negative net margin of 50.83% and a positive return on equity of 39.91%. Bausch Health Companies’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.98 earnings per share. Equities analysts anticipate that Bausch Health Companies will post 3.92 earnings per share for the current year.

In related news, CEO Joseph C. Papa purchased 30,000 shares of the firm’s stock in a transaction on Thursday, February 28th. The stock was purchased at an average cost of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 11.87% of the company’s stock.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. bought a new stake in shares of Bausch Health Companies during the third quarter worth about $223,173,000. Morgan Stanley bought a new stake in shares of Bausch Health Companies during the third quarter worth about $57,631,000. Orbimed Advisors LLC increased its position in shares of Bausch Health Companies by 89.1% during the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after acquiring an additional 1,696,400 shares in the last quarter. Contravisory Investment Management Inc. bought a new stake in shares of Bausch Health Companies during the fourth quarter worth about $104,000. Finally, Financial Sense Advisors Inc. increased its position in shares of Bausch Health Companies by 7.7% during the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock worth $1,556,000 after acquiring an additional 6,050 shares in the last quarter. 54.67% of the stock is owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Featured Article: Correction

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit